Key points are not available for this paper at this time.
Without universal neonatal CMV screening, some infected infants who develop late neurological sequelae may not be recognized and, consequently, they are not able to benefit early from instrumental and therapeutic interventions to limit and/or treat CMV disease.
Chiereghin et al. (Wed,) studied this question.